Human study PLS-00172

Thymosinβ4: a novel assessed biomarker of the prognosis of acute-on-chronic liver failure patient?

Other design · Not reported participants enrolled · not included in the assessments (other)

Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

Only the abstract was available. Essential methods may be missing, which limits what can be judged.

Reports of this study

Every publication, registration and abstract describing this one study. Participants are counted once.

Thymosinβ4: a novel assessed biomarker of the prognosis of acute-on-chronic liver failure patient?primary · Clinics and research in hepatology and gastroenterology · 2014-03-24 · PMID 24674841 · DOI

Design and participants

Design: Other design
Population: Patients with acute-on-chronic liver failure compared with healthy controls, for measurement of endogenous serum thymosin beta-4.
Conditions: Acute-on-chronic liver failure
Planned enrollment (registry): Not reported
Enrolled: Not reported
Randomized: Not reported
Completed follow-up: Not reported
Funding: Research Support, Non-U.S. Gov't (publication type); funder not named in the record.

Intervention and comparator

What each group received. Related peptides, analogs and combinations are never treated as the compound itself.

What the authors reported

As stated in the sources. This is the authors’ account, not Peptide Library’s assessment.

Adverse events

None reported. That is not evidence of safety, and how safety was monitored isn’t described.

The authors concluded (paraphrased): Serum thymosin beta-4 has appreciable value for judging short-term prognosis in acute-on-chronic liver failure, though it is not superior to MELD. Combining it with MELD assesses prognosis better.

Peptide Library’s assessment

An automated assessment, made by AI separately from the authors’ conclusions and not reviewed by a person. How risk of bias is assessed.

Limitations

inappropriate endpoint: Thymosin beta-4 is only measured as an endogenous serum biomarker. It is never administered, so no treatment effect can be inferred.
abstract only: Only a truncated abstract is available. Sample sizes and full results are not reported in the record.

No risk-of-bias assessment has been published for this study’s results.

Claims this study informs

Improves dry eye signs and symptoms: not eligible (not primary study) for “Ocular discomfort and corneal staining”
Is safe for human administration: not eligible (not primary study) for “Adverse events, serious adverse events and discontinuations”

Where each value comes from

author_conclusion: PMID 24674841, abstract (Conclusions, sentences 1-2) · extracted by AI (automated, not verified by a person) · abstract only
design: PMID 24674841, abstract (Background and aim, sentences 1-2; Methods, sentence 1) · extracted by AI (automated, not verified by a person) · abstract only
funding: PMID 24674841, title (publication types) · extracted by AI (automated, not verified by a person) · abstract only
population: PMID 24674841, abstract (Results, sentence 1) · extracted by AI (automated, not verified by a person) · abstract only

Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

These assessments describe published research. Records marked automated were produced by AI under the published methodology and have not been reviewed by a person; they can contain errors. None of this is medical advice, not a statement about any product’s safety for human use, and not a regulatory approval. Peptide Library’s vendor and partner relationships play no part in them (editorial independence).